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Abstract: Pramlintide (Symlin®), a synthetic analog of a neurohormone amylin, was approved 
by the US Food and Drug Administration for use along with premeal insulin in patients with 
type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in 
those patients who are either only on premeal insulin or those receiving the combination of insulin 
and metformin and/or a sulfonylurea. This article reviews the pharmacology, pharmacokinetics, 
dosing, clinical trials, safety, contraindications, and drug interactions of pramlintide therapy. 
A search for published clinical trials and therapeutic reviews in the English language was done in 
the following databases: Iowa Drug Information Service (1966 to July 2008), MEDLINE (1966 
to July 2008), and International Pharmaceutical Abstracts (1970 to July 2008). Pramlintide and 
amylin were used as keywords and title words. References of key articles were also reviewed to 
identify additional publications. Amylin is a 37 amino acid peptide neurohormone cosecreted 
from the beta cells of the pancreas, along with insulin, in response to meals. Amylin lowers 
serum glucose by decreasing glucagon release, slowing gastric emptying and decreasing food 
intake. Pramlintide, a synthetic analog of amylin, reduces 2-hour postprandial blood glucose 
between 3.4 and 5 mmol/L, reduces A1C by 0.2% to 0.7% and has no effect on fasting glucose 
levels. The use of pramlintide was associated with up to a 1.6 kg weight loss. Nausea was the 
most commonly reported adverse event. Pramlintide is an amylin analog that was FDA approved 
for the treatment of type 1 and type 2 diabetes. Its use results in modest reduction of A1C and 
the most frequent side effects are hypoglycemia and nausea.
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Introduction
Currently, 23.6 million Americans have diabetes and the number is expected to 
increase to 29 million by the year 2050 (National Institute of Diabetes and Digestive 
and Kidney Disease 2008) (Boyle et al 2001). The economic burden of diabetes in 
2007 in the United States was estimated to be US$174 billion (American Diabetes 
Association 2008). Type 1 diabetes is cause by an autoimmune destruction of the 
beta cells of the pancreas and affects about 10% of patients with diabetes (American 
Diabetes Association 2005). Until recently, insulin was the only pharmacotherapy 
for type 1 diabetes. Insulin resistance and relative insulin deﬁ  ciency are the causes of 
type 2 diabetes, which accounts for 90% of patients with diabetes (American Diabetes 
Association 2005). In type 2 diabetes, the beta cells of the pancreas are typically 
still functioning, but they are not producing enough insulin to result in euglycemia. 
Insulin, sulfonylureas, metformin, glinides, alpha glucosidase inhibitors, incretin 
mimetics, and thiazolidinediones are used to reduce blood glucose in patients with 
type 2 diabetes. Glycemic control has proven to reduce the complications of type 1 
and type 2 diabetes (Diabetes Control and Complication Research Trial Group 1993; 
United Kingdom Prospective Diabetes Study, 1998a, b; Boyle et al 2001) However, 
despite the availability of multiple agents, 44.5% of patients with diabetes fail to meet 
the American Diabetes Association’s glycemic goals (Hoerger et al 2008).Drug Design, Development and Therapy 2008:2 204
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The physiology of glucose homeostasis is complex and 
insulin and oral agents only correct part of the pathophysiology 
of diabetes. Additional hormones are now being recognized 
for playing a vital role in glucose regulation.
Amylin is a neurohormone that is cosecreted with insulin 
from the beta cells of the pancreas, and its concentrations 
are abnormally low in patients with diabetes (Koda et al 
1992). Pramlintide (Symlin®) is a synthetic analog of amylin 
that was approved in April 2004 by the US Food and Drug 
Administration (FDA) for addition to mealtime insulin 
therapy in patients with type 1 and type 2 diabetes. In patients 
with type 2 diabetes, it is also approved for use in combina-
tion with mealtime insulin with concurrent use of metformin 
and or a sulfonylurea. This paper will review the chemistry 
and preclinical pharmacology, clinical pharmacokinetics, 
clinical trials, safety and tolerability, contraindications, and 
drug interactions of pramlintide in the treatment of type 1 
and type 2 diabetes.
Chemistry and preclinical 
pharmacology
Pramlintide is a synthetic analog of amylin. Amylin is a 37 
amino acid peptide neurohormone that is cosecreted from the 
beta cells of the pancreas along with insulin in response to 
meals (Cooper et al 1987; Koda et al 1992). Amylin levels 
are virtually zero in patients with type 1 diabetes. Patients 
with type 2 diabetes have elevated levels of amylin, but 
relative amylin deﬁ  ciency compared with normal subjects. 
This means that at similar levels of glucose, less amylin 
is secreted in patients with type 2 diabetes compared with 
subjects without diabetes (Koda et al 1992).
Radioligand binding studies have identiﬁ  ed high afﬁ  nity 
amylin receptors in distinct areas of the brain. Speciﬁ  cally, the 
greatest density of amylin receptors are located in the nucleus 
accumbens (NA) and the dorsal vagal complex (DVC), which 
is composed of the caudal portion of the nucleus tractus 
solitarius, also called the area postrema, and dorsal motor 
nucleus of the vagus (Beaumont et al 1993; Sexton et al 
1994). These nuclei process primary vagal afferent input from 
the gastrointestinal tract and provide parasympathetic motor 
innervations back to the gastrointestinal tract. Activation 
of neuronal amylin receptors of the NA and DVC reduces 
food intake and depresses gastrointestinal motility (Lutz et al 
2001; Grabauska et al 2004). Amylin binds to sites in pancre-
atic beta cells that may provide negative feedback inhibition 
of its own secretion and inhibits insulin release (Martinez et al 
2000). Amylin suppresses postprandial glucagon from the 
alpha cells of the pancreas by a neuroendocrine pathway that 
is not completely understood (Weyer et al 2001). Suppressed 
gastrointestinal motility and reduced glucagon release slow 
the rate of glucose inﬂ  ux into the circulation, resulting in 
lower postprandial glucose levels (Figure 1). Exogenous 
amylin is not suitable for pharmacologic use because it 
aggregates into an insoluble compound. Substituting proline 
for the Ala-25, Ser-28, and Ser-29 of amylin results in pram-
lintide, a soluble, stable synthetic analog that is suitable for 
pharmacologic use (Pittner et al 1994).
Pramlintide decreases postprandial glucagon release 
and slows gastric emptying in patients with type 1 and type 
2 diabetes (Kong et al 1997, 1998; Fineman et al 2002a, b). 
In combination with insulin, pramlintide reduces postprandial 
glucose in patients with type 1 or type 2 diabetes without 
increasing insulin levels (Kong et al 1997; Thompson et al 
1997a, c; Weyer et al 2003; Maggs et al 2004). In patients 
with type 1 diabetes, it reduces one-hour postprandial glucose 
by 5–7 mmol/L and 2-hour postprandial glucose by 3.6 to 
5 mmol/L. In patients with type 2, pramlintide reduces one-
hour and two-hour postprandial glucose between 4.8 and 
6 mmol/L and 2.5 and 5 mmol/L, respectively (Table 1).
Clinical pharmacokinetics
Pramlintide acetate is a clear, colorless 600 μg/mL solution 
that is buffered to a pH of 4.0. Pramlintide is available in both 
vials for injections and as pen injector. To reduce the potential 
for dosing errors, patients using a vial and insulin syringe for 
administration should measure their dose in units rather than 
micrograms or milliliters. For example, patients on 30 μg of 
pramlintide should be instructed to measure 5 units rather than 
0.05 mL (Table 2). Pramlintide is also available in a pen that 
has precalibrated doses that allows the patient to dial the dose 
in micrograms. The manufacturer will stop producing the vials 
in 2011 and solely produce the pen, which is precalibrated to 
deliver doses thus eliminating the need for unit conversion. In 
patients with type 1 diabetes, 15 μg before each meal is the 
recommended starting dose. After 3 to 7 days of therapy the 
dose can be increased to 45 μg, then 60 mcg as tolerated if 
glycemic targets are not reached. Patients with type 2 diabetes 
start with a 60 μg dose and may be titrated to 120 μg after 3 to 
7 days. The time to maximum concentration is approximately 
20 minutes and the half life is 29 minutes. Pramlintide is 
primarily eliminated via the kidneys. Dose adjustment is not 
required in elderly patients or patients with moderate to severe 
renal disease (creatinine clearance 20–50 mL/min). There are 
no data available on the safety in patients on dialysis or with 
end-stage renal disease. Drug accumulation is not anticipated 
in hepatic dysfunction (Symlin® Package Insert 2007).Drug Design, Development and Therapy 2008:2 205
Pramlintide as adjunctive therapy for diabetes
Drug interactions
Since pramlintide is buffered to a pH of 4.0 it should be 
incompatible with most insulin products because they are 
buffered to a pH of 7.8. However, in one study, mixing 
Novolin® and Humulin® brands of regular and isophane 
insulins with pramlintide did not affect the pharmacokinet-
ics or efﬁ  cacy of insulin or pramlintide (Weyer et al 2005). 
Despite these results, the pramlintide manufacturer recom-
mends not mixing insulin and pramlintide in the same syringe 
(Symlin® Package Insert 2007). Pramlintide will impair the 
efﬁ  cacy of agents that stimulate gastric motility. It slows the 
absorption of acetaminophen but does not affect the total 
amount absorbed (Kellmeyer et al 2007). The manufacture 
recommends separating the administration of analgesics by 
one hour before or two hours after administration of pram-
lintide to prevent a delay in the analgesic effect. No other 
drug interactions have been reported (Symlin® Package 
Insert 2007).
Phase II studies in type 1 diabetes
In a 4-week double-blind trial, 215 patients with type 1 
diabetes were randomized to receive either placebo; 
pramlintide 30 μg before breakfast, lunch, dinner, and eve-
ning snack (qid); pramlintide 30 μg before breakfast, lunch, 
and dinner (BLD); pramlintide 30 μg before breakfast, 
dinner, evening snack (BDS); and pramlintide 60 μg before 
breakfast and dinner.(Thompson et al 1997b) Fructosamine 
was decreased by 62 mmol/l (7.3%, p = 0.0026) in the qid, 
43 mmol/L (15.3%, p = 0.11) in BLD, 47 mmol/L (10.5%, 
p = 0.025) BDS, 46 mmol/L (11.6%, p = 0.062) in the 60 μg 
group, and 29 mmol/L (11.8%) in placebo group. The daily, 
short-acting insulin doses were decreased by 3.6 units on 
average in the placebo group and reduction of 1–2.3 units 
in the pramlintide groups (no p value reported). The rate of 
hypoglycemia in the pramlintide group was between 12.2% 
and 25%, and the rate in the placebo group was 26.2% 
(no p value). In the pramlintide groups, nausea occurred in 
16% to 37% and anorexia 2% to 9% compared to the placebo 
group rates of 5% and 0% (no p values reported).
Nyholm et al studied the effect of adding 30 μg qid of 
pramlintide before meals in 14 patients with type 1 diabetes 
in a 4-week, placebo-controlled, double-blinded, crossover 
trial (Nyholm et al 1999). Patients were instructed to take 
pramlintide 15 minutes prior to meals and evening snacks. 
Pramlintide therapy reduced serum fructosamine 36 mmol/L 
(10.2%, p = 0.008) lower than placebo therapy. Sixty-minute 
glucagon levels after breakfast were 36.6% (p = 0.005) lower 
and 21.8% (p = 0.02) lower after lunch during pramlintide 
therapy versus placebo. Hypoglycemia was reported by 
78.6% of patients during pramlinitide therapy and 50% 
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Figure 1 Amylin actions. The ﬁ  gure illustrates the three primary mechanisms by which amylin lowers serum glucose.   Amylin activates receptors in the brain which sends signals 
via the vagus nerve to slow gastric emptying and decrease food intake.   Amylin’s neuronal stimulation decreases glucagon production from the pancreas alpha cells.Drug Design, Development and Therapy 2008:2 206
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Table 1 Clinical trials of pramlintide
Author (year) N Design Duration 
(weeks)
With meal doses 
added to insulin
Change from baseline in:
1 h PPG (mmol/L) 
vs placebo
2 h PPG (mmol/L) 
vs placebo
A1C (%) Weight (kg)
Type 1 studies
(Nyholm et al 
1999)
14 DB, CO 4 30 μg qid –7a –4a
(Weyer et al 
2003)
19 R, SB, CO 4 60 μg
+ regular insulin –6a –3.75a
+ lispro –5a –4.75a
(Levetan et al 
2003)
18 4 30 μg qid –4.4a –3.6a
(Fineman et al 
1999)
586 DB, 26 placebo +0.1 +0.3
MC 60 μg tid –0.2b –1.6
90 μg bid –0.1 –0.7
90 μg tid –0.1 –1.6
(Whitehouse 
et al 2002)
480 R, DB, MC 52 placebo –0.16 +1a
30–60 μg qid –0.42b –0.5a
(Ratner et al 
2004)
538 R, DB, MC 52 placebo –0.04 +0.8
60 μg tid –0.29b –0.5b
60 μg qid –0.34b –0.5b
(Edelman et al 
2006)
296 R, DB 29 Placebo –0.5 1.2
30–60 μg tid –0.5 –1.3
Type 2 studies
(Thompson et al 
1998)
203 R, DB, MC 4 placebo –0.27 –0.04
30 μg qid –0.53b –0.36
60 μg tid –0.58b –0.89b
60 μg qid –0.51b –0.72b
(Maggs et al 
2004)
19 R, SB, CO single 
dose
120 μg –4.75a –3.4a
(Gottlieb 1999) 499 DB, MC 26 placebo –0.1 +0.1
90 μg bid –0.3 –0.8
90 μg tid –0.4 –1.3
120 μg bid –0.4b –1.4
(Ratner et al 
2002)
538 R, DB, MC 52 placebo –0.2a 1.0a
30 μg tid –0.3a –0.3a
75 μg tid –0.5a –0.4ab
150 μg tid –0.6b –1.2ab
(Continued)Drug Design, Development and Therapy 2008:2 207
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during placebo treatment. Six (42.9%) of patients reported 
some gastrointestinal adverse effects during the pramlintide 
treatment. No p values were reported for the safety data. The 
main limitation of this trial is the small size.
The effect of adding 30 μg of pramlintide tid to insulin 
pump therapy was studied in 18 patients with type 1 diabetes 
(Levetan et al 2003). Patients’ 24-hour interstitial glucose 
levels were monitored with a continuous glucose monitor-
ing system. At baseline, 59% of glucose measurements were 
over 7.77 mmol/L and 13% were less than 4.44 mmol/L. 
During the pramlintide therapy, the number of hyperglyce-
mic measurements decreased to 48% (no p values reported). 
The average premeal dose of insulin was decreased by 17% 
(no p value reported). The 0 to 3 hour area under the curve 
for glucagon and glucose was reduced by approximately 87% 
(p  0.05) and 86% (p  0.05) after 4 weeks of pramlintide 
treatment, respectively. There was no change in fasting blood 
glucose (p  0.05). Mild to moderate nausea was the most 
commonly reported adverse event. The lack of a control 
group is a major limitation of this trial.
Phase III studies in type 1 diabetes
A 26-week, double-blind, placebo controlled, multi-center 
trial compared the effects of placebo, pramlintide 60 μg 
tid, 90 μg bid, or 90 μg tid in 586 subjects with type 1 
diabetes (Fineman et al 1999). Study therapy was added to 
premeal insulin therapy. The average age of the subjects 
was 38, they had diabetes for a mean of 16 years, and their 
mean glycated hemogolobin (A1C) was 9.0%. At the end 
of the study, the changes in A1C were as follows: +0.1% 
for the placebo, −0.2% for 60 μg tid (p = 0.007), −0.1% for 
90 μg bid (p = 0.048), and −0.1% for 90 μg tid (p = 0.105). 
Changes in insulin doses were not reported, which was a 
major limitation. There was small amount of weight gain in 
the placebo group and weight loss ranged between 0.7 and 
1.6 kg in the pramlintide treated patients (Table 1). Nausea 
(percent not reported) was the most commonly reported side 
effect relative to placebo (p  0.05). The authors stated that 
nausea dissipated during the ﬁ  rst 8 weeks of treatment, but no 
data documenting this was presented. Only patients receiving 
the 90 μg bid or tid dosing had a higher rate of hypoglycemia 
when compared to placebo (no p value reported).
In a 52-week, double-blind, multicenter trial, 480 patients 
with type 1 diabetes were randomized to receive either 
premeal injections of placebo or 30 μg of pramlintide 
4 times per day in addition to their current insulin regimen 
(Whitehouse et al). If A1C reductions were less than 1% at 
week 13, pramlintide-treated patients were re-randomized at 
week 20 to receive either 30 or 60 μg pramlintide 4 times a 
day. This second randomization was done by an unblinded 
third party. The patients in the placebo group remained on 
placebo. The study population demographics were similar in 
each group and were as follows: over 90% Caucasian, BMI 
(body mass index) of 25 kg/m2, A1C of 8.8%, 55% male, 
and average age of 40 years. Average A1C was reduced by 
0.39% in the pramlintide groups and 0.12% in the placebo 
(p = 0.0071). The authors did not report the changes in A1C 
for the 30 μg and 60 μg of pramlintide groups separately. 
At the end of the trial the total daily insulin dose was 2.3% 
higher than at baseline in the pramlintide group (no p value 
for comparison to baseline was reported). The placebo 
group patients had a 10.3% (p = 0.017) increase in insulin. 
The treatment difference were statistically significant 
(p = 0.0176). An approximate 1 kg weight loss was seen 
Table 1 (Continued)
Author (year) N Design Duration 
(weeks)
With meal doses 
added to insulin
Change from baseline in:
1 h PPG (mmol/L) 
vs placebo
2 h PPG (mmol/L) 
vs placebo
A1C (%) Weight (kg)
(Hollander et al 
2003b)
498c R, DB, MC 52 placebo –0.22a +0.5a
90 μg bid –0.35 –0.5
120 μg bid –0.62b –1.4b
(Riddle et al 
2007)
212 DB, PC 16 placebo –1.9 –0.36 0.7
60–12 μg bid-tid –3.1 –0.70a –1.6
aThese data were extrapolated from graphs as the absolute values were not listed in the text of the published study.
bp  0.05.
cThe study initially included a 60 mcg tid group (N = 158), but this group was not included in the analysis so the original N = 656.
Abbreviations: R, randomized; DB, double blind; MC, multi-center; PPG, postprandial glucose; SB, single blind; CO, crossover.Drug Design, Development and Therapy 2008:2 208
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at 13 weeks in the pramlintide group compared to about a 
0.25 kg weight gain in the placebo group (p  0.001). By 
the end of the blinded study phase, the pramlintide group 
regained 0.5 kg; making this groups final weight loss 
only 0.5 kg. By the end of 52 weeks, the placebo group 
gained 1 kg (p  0.05). Two-hundred thirty-six patients 
from all groups of this study were recruited for a 52-week, 
open-label, extension phase and given pramlintide 30 μg 
qid before meals. At the end of the extension phase, the 
group that started on pramlintide for the ﬁ  rst time had an 
approximate decrease in A1C by 0.35% (p  0.05). Weight 
started to return to baseline values in week 65 in the subjects 
that received pramlintide for the entire 104 week period 
(Table 1). Severe hypoglycemia, deﬁ  ned as needing assis-
tance of another person, intravenous glucose, or glucagon, 
was similar between all groups. Nausea was the most 
common reported adverse event and the primary reason for 
withdrawal, 7.4% in the pramlintide and 1.7 % in the placebo 
groups (p valued not reported). During the second phase, 
the group who was switched from placebo to pramlintide 
had a 40.5% nausea rate and a 12.6% anorexia rate. Those 
who continued on pramlintide had an incidence of nausea 
of 14.4% and anorexia 1.6% in the second year (no p values 
were reported).
In a 52-week randomized, double-blind, placebo-
controlled, multi-center study, 651 patients with type 1 
diabetes were treated with either 60 μg tid, 60 μg qid, 
90 μg tid or placebo prior to meals (Ratner et al 2004). The 
average subject was approximately 41 years old, had a BMI 
of 26.5 kg/m2, had diabetes for 9 years, and had a A1C of 
8.9%. Greater than 90% of subjects were Caucasian and 51% 
were male. At 26 weeks, there was a statistically signiﬁ  cant 
decline in A1C in the 60 μg tid and 60 μg qid groups of 
0.41% (p = 0.012) and 0.39% (p = 0.012) compared to a 
decrease of 0.18% in the placebo group. The investigators did 
not report the efﬁ  cacy data of the 90 μg group because this 
higher dose had been shown to have a higher incidence 
of side effects compared to the lower doses (no reference 
was listed). At 52 weeks, change in glycemic control in the 
pramlintide-treated patients was still signiﬁ  cantly different 
(Table 1). The average daily insulin dose decreased by 3% 
to 6% in the pramlintide group, and there was no change in 
the placebo group (p value not reported). At 52 weeks an 
approximate 0.5kg weight loss was seen in both pramlintide 
treated groups compared to 0.7 weight gain (p  0.05) in the 
placebo group. Nausea again was reported as the only adverse 
event. The authors state that the nausea usually diminished 
in the ﬁ  rst 4 weeks of therapy but no data was reported. In 
the ﬁ  rst 4 weeks of the study, a 4-fold increase in the rate 
of hypoglycemia was seen the pramlintide groups versus 
placebo (p value not reported).
The effects of adding pramlintide to either intensive-
insulin therapy or insulin-pump therapy were studied in 
296 patients with type 1 diabetes in a 29-week, double-
blind, placebo-controlled, randomized, non-inferiority trial 
(Edelman et al 2006). Premeal pramlintide (15 μg) was 
increased weekly by 15 μg to a maintenance dose of 60 μg 
during the 4-week initiation period. In both groups, insulin 
was adjusted during the maintenance period to achieve self-
monitored preprandial glucose levels of 6.1 to 7.7 mmol/L 
and self-monitored postprandial glucose levels of 7.7 to 
9.9 mmol/L. Hypoglycemia was the primary endpoint and 
the secondary endpoint was change in postprandial glucose, 
A1C, insulin doses, and weight. The baseline average A1C 
was 8.1%, average BMI was 27.8 kg/m2, the average duration 
of diabetes was 19 to 21 years, 40.8% to 48.6% of patients 
were male, and the average age was 41 years. The baseline 
average total insulin dose in patients on multiple injections 
per day was 66.5 ± 32.6 units and 47.3 ± 20.2 units in patients 
on an insulin pump. The ﬁ  nal total daily insulin doses were 
12% lower in the pramlintide-treated subjects compared to 
1% higher in the placebo-treated patients. Approximately, 1% 
of pramlintide treated subjects were on the 15 μg dose, 21% 
were on the 30 μg dose, 1% were on the 45 μg dose, and 
78% were on the 60 μg dose. The A1C mean change in the 
pramlintide and insulin groups was 0.5% (p  0.001 versus 
baseline). There was no p value reported for the comparison 
of the changes in A1Cs in the pramlintide group versus 
the placebo group. In patients treated with pramlintide, 
postprandial glucose values were below target 68%, 71%, 
and 70% of the time after breakfast, lunch, and dinner, 
respectively. And in the placebo-treated patients, the percent-
age of time that breakfast, lunch, and dinner postprandial 
glucoses were below target was 51%, 61%, and 58%, respec-
tively (p  0.0001). Weight was reduced by pramlintide 
therapy (1.3 ± 0.3 kg) and increased with placebo therapy 
Table 2 Pramlintide dosage
Dose (μg) Units on a U-100 
syringe
mL
15 2.5 0.025
30 5 0.05
45 7.5 0.075
60 10 0.1
120 20 0.2Drug Design, Development and Therapy 2008:2 209
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(1.2 ± 0.24 kg, p  0.0001). Adverse events that occurred 
more frequently were reduced appetite, vomiting and nausea. 
Suppressed appetite occurred in 8.8% of pramlintide-treated 
patients and 2% in the placebo-treated group (p  0.05). 
Vomiting occurred in 13.5% and 6.1% of the pramlintide 
and placebo groups (p  0.05). Nausea was reported by 
62.8% of pramlintide-treated subjects and 36.1% of pla-
cebo-treated patients (p  0.01). The pramlintide event rate 
per patient-year of severe hypoglycemia was between 0.54 
and 0.75 compared to 0.28 and 0.42 in the placebo group 
(p  0.05). Marreoro et al (2007) assessed satisfaction of 
pramlintide therapy in 266 patients from the Edelman study 
(Edelman et al 2006; Marrero et al 2007). On all but two 
patient-reported outcomes, patients treated with pramlintide 
reported improved satisfaction (p  0.05) with their diabetes 
treatment.
Phase II studies in type 2 diabetes
The ﬁ  rst published trial of subjects with type 2 diabetes 
was single-blind, randomized, cross-over trial (N = 24) 
(Thompson et al 1997a). Ten patients were treated with 
insulin only, 2 patients received insulin and oral agents, 
7 patients were on oral agents, and 5 patients were managed 
with diet alone. Subjects were given a 100 μg/h pramlintide 
infusion for 5 hours. And at the beginning of the ﬁ  rst hour 
the patients ingested 7 kcal/kg of Sustacal®. The mean insulin 
levels were 43% lower during pramlintide infusion when 
compared to placebo infusion (p = 0.00025). More patients 
reported nausea (58%) while receiving pramlintide compared 
to patients on placebo (25%, no p values reported).
The effect of adding premeal pramlintide 30 μg qid, 
60 μg tid and 60 μg qid to insulin therapy was studied in 
203 subjects with type 2 diabetes (Thompson et al 1998). 
This was a randomized, double-blind, placebo-controlled, 
multicenter, 4-week trial. By the end of the trial, fruc-
tosamine was decreased by 17.5 mmol/L (5.8%) in the 
30 μg group (p = 0.029), 24.1 mmol/L (8.0%) in 60 μg tid 
group (p = 0.003), 22.6 mmol/L (7.6%) in 60 μg qid group 
(p = 0.001), and 3.5 mmol/L (1.1%) in the placebo group. 
Changes in weight and A1C are listed in Table 1. The change 
in weight was not statistically significant. Nausea was 
reported by 10% to 14% of pramlintide-treated subjects. 
The rate of hypoglycemia was similar in all groups, but no 
incidence or p value was reported.
A single-blind, placebo-controlled trial examined the 
effects of varying the time between administration of 
pramlintide 120 μg and initiation of the meal (Maggs et al 
2004). Patients (N = 19) had type 2 diabetes and were 
treated with lispro at time 0 relative to the meal. Subjects 
received subcutaneous placebo or pramalintide at −15, 0, +15, 
or +30 minutes relative to a standardized meal. Relative to 
placebo glucose 0 to 4 hour area under the curve was reduced 
by 42% (p = 0.05), 81% (p  0.05), 73% (p  0.05) and 
59% (p  0.05) when pramlintide is given at −15, 0, +15, 
or +30 minutes, respectively. Percent reduction and p values 
are for comparison to placebo. Hypoglycemia was the only 
reported adverse event (the percent incidence and p value 
were not reported).
Phase III studies in type 2 diabetes
The earliest large-scale, long-term trial in patients with 
type 2 diabetes examined the effect of pramlinitide in a 
26-week, multi-center, double-blind, placebo-controlled 
study (N = 499) (Gottlieb 1999). The mean baseline A1C was 
9.4%, the average age was 58 years, and the mean duration 
of diabetes was 13.5 years. Either 90 μg bid, 90 μg tid, 
120 μg bid of premeal pramlintide, or placebo was added to 
insulin therapy. At 26 weeks, the A1C decreased by 0.1%, 
0.3% (p = 0.068), 0.4% (p = 0.079), and 0.4% (p = 0.048) 
in the placebo, 90 μg bid, 90 μg tid, and 120 μg bid groups, 
respectively. The total daily insulin dose increased in the 
placebo group and decreased in the pramlintide treated 
patients (p = 0.0002); the authors did not report the percent 
changes of insulin doses. At the end of the trial period, weight 
had also changed by +0.1 ± 0.3 kg, −0.8 ± 0.3 kg, −1.3 ± 
0.3 kg, −1.4 ± 0.3 kg in the placebo, 90 μg bid, 90 μg tid, 
and 120 μg bid groups, respectively. Nausea was the only 
reported side effect. The rate of hypoglycemia was equivalent 
in all groups. No statistical analyses of the comparisons to 
baselines values were reported.
In a 52-week trial, Ratner et al (2002) studied the effects 
of pramlintide in patients with type 2 diabetes who were 
on insulin. In this multi-center, double-blind trial, patients 
were randomized to placebo, 30 μg, 75 μg or 150 μg of 
pramlintide tid. In addition to insulin, up to 8% of each group 
was treated with sulfonylureas and up to 18.9% received 
metformin as a part of their baseline regimen. There were no 
statistical differences in baseline demographics or treatment 
of diabetes. The subjects’ average age ranged from 55.5 to 
57.5 years, 56% to 62% of each group was male, each group 
was between 76% and 81% Caucasian, the BMI ranged from 
30.4 to 31.1 kg/m2 and the baseline A1C ranged from 9.0% to 
9.3%. According to values extracted from a graph, there was 
a 0.2% (p  0.05), 0.3% (p  0.05), 0.5% (p  0.05), 0.6% 
(p  0.05) decrease in A1C in the placebo, 30 μg, 75 μg, and 
150 μg groups, respectively. The changes for the placebo, Drug Design, Development and Therapy 2008:2 210
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30 μg, and 75 μg groups were extracted from a ﬁ  gure because 
the results were not reported in the text of the article. Insulin 
doses were increased by 15.4% in the placebo group and by 
7.9% to 10.9% in the pramlintide groups (statistical signiﬁ  -
cance not reported). Similar to other studies a weight loss 
was observed in the pramlinitide-treated subjects (Table 1). 
Nausea occurred in 16.9% of the placebo group compared 
to 14.8% in the 30 μg group, 26.5% in the 75 μg group, and 
22.9% in the 150 μg group (p values were not reported). 
Similar with other studies, the authors reported transient 
nausea but did not present any evidence to support this state-
ment. All groups had a similar incidence of hypoglycemia, 
but no incidence or statistical results were reported.
In another 52-week, double-blind, multi-center trial 
patients with type 2 diabetes (N = 656) were randomized to 
receive placebo, 60 μg tid, 90 μg bid or 120 μg bid of pram-
lintide prior to meals (Hollander et al 2003b). In addition to 
insulin, patients were also treated with metformin (14%), 
sulfonylureas (10%), or the combination of sulfonylureas and 
metformin (2%). The investigators decided not to report the 
ﬁ  ndings from the 60 μg tid group because, while this study 
was ongoing, information from another study, which was not 
referenced, became available that indicated 60 μg bid was 
not effective. The results of the other groups are presented 
in Table 1. Insulin and oral hypoglycemic therapy remained 
stable throughout the trial in all groups. Nausea was the most 
common side effect; the percent incidence and p value were 
not reported. During the ﬁ  rst 4 weeks of therapy, there were 
three times more hypoglycemic episodes in the 120 μg group 
compared to placebo (p  0.05).
Riddle et al (2007) investigated the efﬁ  cacy and safety of 
the addition of pramlintide (60 or 120 μg bid/tid) to patients 
with an uncontrolled A1C on insulin glargine (with or without 
oral anti-diabetes medications) in a 16-week, double-blind, 
placebo-controlled trial involving 212 patients with type 2 
diabetes. Patients were on average 55 years of age. Baseline 
BMI was 35 kg/m2 and HbA1c was 8.5%. Patients were 
titrated to the 120 μg dose of pramlintide 3 to 7 days after 
initiation if no clinically signiﬁ  cant nausea occurred. Ninety-
three percent of patients were titrated to the 120 μg dose. 
Once the maintenance dose was achieved, investigators were 
instructed to titrate insulin glargine doses to achieve fasting 
glucose concentrations of 3.9 mmol/L to 5.6 mmol/L. 
Two co-primary endpoints were evaluated. The ﬁ  rst was 
change in A1C from baseline to week 16. The second 
co-primary composite endpoint assessing the percentage of 
patients meeting all of the following criteria: 1) A1C  7% 
or an A1C reduction 0.5% 2) average daily postprandial 
glucose increments 40 mg/dL 3) no weight gain 4) and no 
severe hypoglycemia (requiring assistance). A1C values in 
the pramlintide-treated patients were signiﬁ  cantly reduced 
from baseline versus placebo-treated patients (−0.7 ± 0.11% 
versus −0.36 ± 0.08%, p  0.05). The mean A1C values 
at week 16 for pramlintide and placebo were 7.8% and 
8.1%, respectively. Signiﬁ  cantly more pramlintide-treated 
patients achieved the composite endpoint versus placebo 
(25 versus 7%; p  0.001). Weight loss was seen with 
pramlintide and weight gain was seen with placebo (−1.6 ± 
0.3 kg versus +0.7 ± 0.3 kg; p  0.0001). Nausea occurred 
in 31% of pramlintide and 10% of placebo treated patients. 
Hypoglycemia occurred in 44% of pramlintide and 47% of 
placebo treated patients (no p value reported). No treatment 
related severe hypoglycemia occurred in either group.
Rubin et al assessed the treatment satisfaction of patients 
treated with pramlintide and insulin therapy in an open-label 
study that included 240 patients with type1 diabetes and 
160 patients with type 2 diabetes (Rubin and Peyrot 2007). 
Seven-point glucose proﬁ  les and weight were assessed at 
baseline, 1 month, 3 months, and 6 months. A1C was assessed 
at baseline, 3, and 6 months. At week 1, 3, and 6 months, 
patients completed a 14-item treatment satisfaction question-
naire (TSQ). The TSQ assessed how the patients felt the study 
medication affected control of glucose, appetite, weight, 
adherence, number of injections, well-being, and willing-
ness to continue pramlintide in the future. The questions 
were clustered into 3 sets of categories – glucose control, 
eating/weight control, and general beneﬁ  ts. All items were 
scored (maximum score of 2 and minimum score of –2). 
A score of 0 indicates no advantage of pramlintide over the 
patient’s previous diabetes regimen. Positive scores indicate 
an advantage of pramlintide and negative scores indicate a 
disadvantage of pramlintide. Patients rated the pramlintide 
treatment regimen signiﬁ  cantly better than their previous 
treatment in all 3 sets of items – glucose control, eating/
weight control, and general beneﬁ  ts at 1, 3, and 6 months. 
Treatment satisfaction was higher for those who experienced 
better clinical outcomes (decreases in insulin, weight, and 
postprandial glucose levels). The majority of patients (96%) 
said they would like to continue using pramlintide.
Elkind-Hirsch et al reported the real world, clinical 
experiences when pramlintide was added to the treatment 
regimens of insulin-requiring patients with type 2 diabetes 
(Elkind-Hirsch et al 2008). The population consisted of 
54 women and 38 men in the age range of 24 to 80 years. The 
majority of patients were overweight or obese. Retrospec-
tive analysis of data showed that 24 weeks of pramlintide Drug Design, Development and Therapy 2008:2 211
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therapy in addition to insulin (with or without other oral 
anti-diabetic medications) resulted in a signiﬁ  cant decrease 
in A1C (8.32 ± 0.17 to 7.86 ± 0.16%; p = 0.0125). Therapy 
with pramlintide also resulted in a signiﬁ  cant decrease in 
body weight (104.4 ± 2.1 to 103.2 ± 2.07 kg; p = 0.029) and 
BMI (35.2 ± 0.6 to 34.7 ± 0.6 kg/m2; p = 0.019). There were 
no signiﬁ  cant differences between baseline and follow-up on 
abdominal girth, total cholesterol (TC), triglycerides (TG) or 
high-density lipoprotein cholesterol (HDL-C). Low-density 
lipoprotein cholesterol (LDL-C) was reduced by 0.19 mmol/L 
(p = 0.029). This change, according to the authors, could not 
be attributed to changes in lipid lowering medications.
Post-hoc analysis
A post-hoc analysis of Ratner et al (2002) and Hollander et al 
(2003b) examined changes in A1C and weight in African 
American, Hispanic, and Caucasian patients treated with 
either placebo or pramlinitide 120 μg bid or 15 μg tid (Maggs 
et al 2003). After 52 weeks of therapy, there was a 0.7%, 
0.3% and 0.5% reduction in A1C in African-Americans, 
Hispanics and Caucasians, respectively. African-Americans 
lost 4.1 kg, Caucasians lost 2.4 kg, and Hispanic lost 2.3 kg. 
There were no p values reported for any of these comparisons, 
which is a limitation of this trial.
In a post-hoc analysis of the data from the same 
patients in the Riddle et al (2007) trial, Wysham et al 
(2008) described the effects of pramlintide as an adjunct 
to basal insulin on markers of cardiovascular risk includ-
ing: weight, high sensitivity C-reactive protein (hs-CRP), 
TGs, HDL-C, LDL-C, and blood pressure. At baseline, the 
average hs-CRP concentrations were 3 mg/L and mean 
TGs were 176 mg/dL. Baseline LDL-C was 94 mg/dL and 
104 mg/dL and baseline HDL-C was 49 mg/dL and 48 mg/dl 
in the placebo and pramlintide groups, respectively. Baseline 
blood pressure was 129/79 mmHg and 130/79 mmHg in 
the placebo and pramlinitide groups, respectively. Slightly 
more patients were taking metformin in the placebo group 
versus the pramlintide group (75 versus 67); whereas, 
slightly more patients were taking thiazolidinediones in the 
pramlintide group versus the placebo group (32 versus 20). 
At week 16, hs-CRP was reduced significantly more 
in the pramlintide group than in the placebo group 
(−0.8 ± 0.2 mg/dL versus 0.1 ± 0.2 mg/dL; p  0.01). There 
were favorable trends in TG reduction with pramlintide 
versus placebo especially in those with TGs  150 mg/dL 
and 200 mg/dL at baseline. However, these changes were 
not statistically signiﬁ  cant versus placebo. As reported pre-
viously, there were signiﬁ  cant reductions in body weight in 
the pramlintide group versus the placebo group. There were 
no statistically signiﬁ  cant changes versus placebo on LDL-C 
or HDL-C. Although systolic and diastolic blood pressures 
were reduced more in the pramlintide treated patients versus 
placebo treated patients, there was no statistical signiﬁ  -
cance between the two groups. The authors concluded that 
pramlintide as an adjunct to basal insulin was associated 
with improvements in several cardiovascular risk markers 
(hs-CRP, body weight, and TGs) and that long term trials 
are warranted to determine the drug’s potential effects on 
cardiovascular risk.
A post-hoc analysis the Gottlieb (Gottlieb 1999) and 
Hollander et al ( 2003b) trials examined the effects of pram-
lintide therapy in a subpopulation of patients with A1C of 
7.5% to 8% (Hollander et al 2003a). Insulin doses were not 
changed in the 166 patients treated with either placebo or 
pramlintide 120 μg bid. The ﬁ  nal A1C was 0.1% higher in 
the placebo group but 0.43% lower in the pramlintide treated 
group (p  0.05).
Safety and tolerability
None of the long term studies reported evidence of hepatic, 
renal, cardiovascular, or pulmonary toxicity associated with 
pramlintide therapy (Fineman et al 1999; Gottlieb 1999; 
Whitehouse et al 2002; Hollander et al 2003b; Ratner et al 
2002, 2004). All of these studies reported nausea as the 
main side effect. Most of the studies reported the nausea 
as transient, lasting between 2 and 8 weeks (Fineman et al 
1999; Whitehouse et al 2002; Gottlieb 1999; Ratner et al 
2002, 2004). However, none of the studies reported data to 
document the reduction of nausea. The rate of nausea varied 
between 10% and 59% (Thompson et al 1998; Whitehouse 
et al 2002; Hollander et al 2003b, Ratner et al 2002, 2004). 
and the percentage of patients reported to have dropped out 
of the study because of nausea was between 5.4% and 62.8% 
(Whitehouse et al 2002; Ratner et al 2002, 2004; Edelman 
et al 2006). The use of larger doses was associated with a 
higher incidence of nausea (Hollander et al 2003b; Ratner 
et al 2002, 2004; Edelman et al 2006, Riddle et al 2007). 
Hollander et al (2003b) found the increased nausea was 
not associated with more weight loss and that the incidence 
of nausea was not increased by the concomitant use of 
metformin.
As blood glucose approaches euglycemia, the risk for 
hypoglycemia increases (United Kingdom Prospective 
Diabetes Study Group 1998a, b; Boyle et al 2001). In all of 
the long term trials, the rate of hypoglycemia was similar 
in the pramlintide groups compared to the placebo groups Drug Design, Development and Therapy 2008:2 212
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(Gottlieb 1999; Ratner et al 2002; Whitehouse et al 2002; 
Edelman et al 2006; Riddle et al 2007). In one 52-week study, 
hypoglycemia was 4 times more likely in the ﬁ  rst 4 weeks 
of pramlintide therapy compared to placebo, but after the 
ﬁ  rst 4 weeks the risk was equal (Ratner et al 2004; Edelman 
et al 2006). Hollander et al (2003b) found a greater risk of 
hypoglycemia during treatment with pramlintide 120 μg bid 
compared to the 60 μg bid, 90 μg bid, and placebo groups. 
This difference was only seen during the ﬁ  rst 4 weeks of 
this 52 week study. Another study also found that the 90 μg 
bid and tid groups had a higher rate of hypoglycemia than 
the groups treated with placebo or 60 μg tid (Fineman et al 
1999). To minimize the risk of hypoglycemia, manufacture 
recommends reducing the dose of short-acting premeal 
insulin by 50% when initiating pramlintide (Symlin® Pack-
age Insert 2007). To date the agent has not been reported to 
cause pancreatitis.
Contraindications
Pramlintide slows gastric emptying, therefore, is not recom-
mended in patients with gastroparesis. In addition, history 
of frequent hypoglycemia is a relative contraindication to 
pramlintide because it will increase the risk of low blood 
glucose. Therapy with this agent is not advisable in patients 
that are not compliant with current therapy or those that are 
not willing to monitor blood glucose frequently (Symlin® 
Package Insert 2007).
Discussion
The beneﬁ  ts of pramlintide are reduction of A1C, postpran-
dial glucose, a potential reduction of total daily insulin dose, 
and possible weight loss. The studies indicate that pramlintide 
reduces A1C between 0.2% and 0.4% in patients with type 1 
diabetes and 0.4% and 0.6% in patients with type 2 diabetes 
with an initial A1C of 8% to 9% (Fineman et al 1999; Gottlieb 
1999; Whitehouse et al 2002; Ratner et al 2002, 2004; 
Edelman et al 2006; Riddle et al 2007). Additional study of 
the use of pramlintide therapy in patients with A1C over 9.0% 
is needed. Pramlintide typically reduces 2-hour postprandial 
glucose between 4 and 6 mmol/L and has a minimal affect 
on fasting glucose. The 0.5 to 1 kg weight loss observed 
with pramlintide therapy may be beneﬁ  cial compared to the 
increase in weight which is commonly seen with insulin, 
sulfonylureas and thiazolidinediones (Fineman et al 1999; 
Gottlieb 1999; Ratner et al 2002, 2004; Whitehouse et al 
2002; Hollander et al 2003b). However, findings after 
104 weeks of therapy suggest that the weight loss may be 
transient (Whitehouse et al 2002). One investigator ruled out 
the possibility that nausea may be the reason for weight loss 
(Hollander et al 2003b). Randomized controlled trials longer 
than one year are necessary to establish the long-term weight 
loss potential of pramlintide.
The major limitations to pramlintide therapy include 
hypoglycemia, nausea, subcutaneous route of administration, 
and the use and expense of another medication. The rate of 
hypoglycemia in the pramlintide group was 2 to 4 times 
greater than placebo group’s rate in the ﬁ  rst 4 weeks of 
therapy (Ratner et al 2002; Hollander et al 2003b) The manu-
facturer recommends reducing the dose of premeal insulin by 
50% when starting pramlintide. No dose adjustment baseline 
therapy with sulfonylurea or metformin is recommended. 
However, close monitoring of blood glucose levels is impera-
tive whenever pramlintide therapy is started. Nausea was the 
most frequently reported side effect and the most common 
reason for subject withdrawal. Most investigators stated that 
nausea dissipated after 4 weeks of therapy, but no data were 
reported to support these statements.
Pramlintide is indicated for use with mealtime insulin and 
combining both agents in the same syringe for simultaneous 
administration would reduce the number of injections neces-
sary. However, the package insert states pramlintide should 
not be mixed in the same syringe with insulin (Symlin® 
Package Insert 2007). However, one study that showed that 
mixing pramlintide and isophane or regular insulin into the 
same syringe does not change the pharmacokinetics or phar-
macodynamics of either agent (Weyer et al 2005). Additional 
studies to determine the compatibility of mixing pramlintide 
and a variety of insulin products are warranted.
To our knowledge, there are no pharmacoeconomic 
studies of pramlintide therapy. The average wholesale price 
of a 0.6 mg/mL 5 ml vial is US$127 (Rice 2008) It would cost 
about US$127 to $254 per month for a patient who uses 30 to 
60 μg tid. Studies must be done to determine cost beneﬁ  t.
Conclusion
Pramlintide is an amylin analog that can be used with meal-
time insulin in the treatment of type 1 and type 2 diabetes. In 
patients with type 2 diabetes, pramlintide can also be added 
to sulfonylurea monotherapy, metformin monotherapy, 
the combination of a sulfonlyurea and metformin, or the 
combination of sulfonylurea, metformin and insulin. Therapy 
with pramlintide reduces A1C by 0.2% to 0.6% and the 
2-hour postprandial glucose by 3.4 to 5 mmol/L. In the 1-year 
studies, pramlintide therapy decreased weight modestly, but 
in one 52-week, open-label, extension trial weight returned 
to baseline levels. There is an ongoing trial that examines Drug Design, Development and Therapy 2008:2 213
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the effectiveness of pramlintide as a weight loss agent 
(www.ClinicalTrials.gov, 2008). Pramlinitide has a favor-
able safety proﬁ  le and minimal contraindications. Transient 
nausea is the most common adverse event. To reduce the risk 
of hypoglycemia, a reduction of premeal insulin by 50% and 
close glucose monitoring is warranted.
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